CP
EWTX icon

Castleview Partners’s Edgewise Therapeutics EWTX Stock Holding History

Castleview Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,204
Closed -$296K – 948
2024
Q1 		$296K Buy
+16,204
New +$258K 0.17% 138

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Castleview Partners's EWTX Position: Q2 2024 in Review

Castleview Partners sold out of Edgewise Therapeutics (EWTX) in Q2 2024, closing a stake of 16,204 shares — an estimated $296K sold.

Castleview Partners first reported a position in EWTX in Q1 2024 and held it in 1 quarter. The position peaked at $296K in Q1 2024. 140 funds tracked by Wall St. Rank hold EWTX as of Q2 2024.

  • Castleview Partners reported no remaining Edgewise Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 16,204 Edgewise Therapeutics shares in Q2 2024, an estimated $296K.
  • Castleview Partners first reported a position in Edgewise Therapeutics in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's Edgewise Therapeutics position peaked at $296K in Q1 2024.
  • 140 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.